Audio-based Mental Health Intervention Study

Sponsor
Penn State University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05555745
Collaborator
(none)
126
2
31

Study Details

Study Description

Brief Summary

This is a study on an audio-based digital intervention designed to reduce symptoms of depression. Participants who experience at least moderate symptoms of depression will be invited to participate in the study. Participants will be randomly assigned to receive one of two audio-based digital interventions. The experimental intervention based on behavioral activation treatment for depression. The control intervention is based on self-monitoring. Depression symptoms and related mental health symptoms, as well as experiences with the intervention, will be assessed at baseline (pre-randomization), mid-intervention (1 week post-randomization), post-intervention (2 weeks post-randomization) and follow-up (4 weeks post-randomization)

Condition or Disease Intervention/Treatment Phase
  • Device: Audio-based behavioral activation intervention
  • Device: Audio-based self-monitoring intervention
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
126 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Audio-based Mental Health Intervention Study
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
May 1, 2025
Anticipated Study Completion Date :
May 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Audio-based behavioral activation intervention

This intervention consists of two audio-based sessions delivered one week apart. The first session lasts approximately 30 minutes, and the second session lasts approximately 15 minutes. The sessions are audio recordings. The first session introduces behavioral activation and provides instruction for how to schedule and engage in positively reinforcing activities. The second session recaps the principles of behavioral activation and guides participants through methods of troubleshooting. After each session, participants are asked to create an activity schedule for the coming week. Then, each day in the week following each session, participants receive an email with a survey asking them to report on their activity and mood in the previous day.

Device: Audio-based behavioral activation intervention
Access to audio-based behavioral activation intervention

Active Comparator: Audio-based self-monitoring intervention

This intervention consists of two audio-based sessions delivered one week apart. The first session lasts approximately 30 minutes, and the second session lasts approximately 15 minutes. The sessions are audio recordings. The first session introduces information about emotion and provides instruction for how to track emotion using self-monitoring. The second session provides more information about emotion and recaps instructions for self-monitoring. Each day in the week following each session, participants receive an email with a survey asking them to report on their mood in the previous day.

Device: Audio-based self-monitoring intervention
Access to audio-based self-monitoring intervention

Outcome Measures

Primary Outcome Measures

  1. Change in symptoms of depression [Measured at baseline, 1-week, 2-week, 4-week. Outcome is change from baseline to each of the subsequent time points.]

    Change in symptoms of depression as measured by Beck Depression Inventory-FastScreen (7 items, possible range = 0-21)

Secondary Outcome Measures

  1. Change in symptoms of depression [Measured at baseline, 1-week, 2-week, 4-week. Outcome is change from baseline to each of the subsequent time points.]

    Change in symptoms of depression as measured by Patient Health Questionnaire-9 (9 items, range = 0-27)

  2. Change in symptoms of depression, anxiety, and stress [Measured at baseline, 1-week, 2-week, 4-week. Outcome is change from baseline to each of the subsequent time points.]

    Change in symptoms of depression, anxiety, and stress as measured by Depression Anxiety Stress Scales-Short Form (21 items, range = 0-42 per depression, anxiety, or stress sub-scale)

  3. Change in positive affect [Measured at baseline, 1-week, 2-week, 4-week. Outcome is change from baseline to each of the subsequent time points.]

    Change in positive affect, as measured by the Positive and Negative Affect Schedule, positive affect sub-scale (10 items, range = 10-50)

  4. Change in negative affect [Measured at baseline, 1-week, 2-week, 4-week. Outcome is change from baseline to each of the subsequent time points.]

    Change in negative affect, as measured by the Positive and Negative Affect Schedule, negative affect sub-scale (10 items, range = 10-50)

  5. Change in behavioral activation [Measured at baseline, 1-week, 2-week, 4-week. Outcome is change from baseline to each of the subsequent time points.]

    Change in behavioral activation, as measured by the Behavioral Activation for Depression Scale - Short Form (9 items, range = 0-54)

Other Outcome Measures

  1. Intervention satisfaction [Measured at post-intervention (2-weeks)]

    Satisfaction with the intervention, as measured with the mHealth Satisfaction Questionnaire (14 items, range = 14-70)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adult age 18 or older

  • Score in the moderate or higher range on the BDI-FastScreen

  • Moderate or higher depression confirmed by DIAMOND interview

  • Proficient English reading, writing, and speaking ability

  • Able to provide consent

  • Provide informed consent

Exclusion Criteria:
  • Below 18 years of age

  • Score below the moderate range on the BDI-FastScreen

  • DIAMOND interview does not confirm moderate or higher depression

  • Unable to read, write, and speak in English

  • Unable to provide consent

  • Do not provide informed consent

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Penn State University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Michelle G. Newman, Professor, Penn State University
ClinicalTrials.gov Identifier:
NCT05555745
Other Study ID Numbers:
  • STUDY00020667
First Posted:
Sep 27, 2022
Last Update Posted:
Sep 27, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Michelle G. Newman, Professor, Penn State University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 27, 2022